Abstract Number: 1997 • 2019 ACR/ARP Annual Meeting
Histologic and Clinical Correlates of Ultrasound Measures of Joint Inflammation: Analysis of RA Tissue Obtained by Ultrasound Guided Biopsy in Phase 2 of the Accelerating Medicines Partnership RA Network
Background/Purpose: The AMP-RA network applies cutting edge molecular single cell technologies to study synovial tissue obtained from rheumatoid arthritis (RA) patients using US guided synovial…Abstract Number: 480 • 2019 ACR/ARP Annual Meeting
Not Achieving Clinical Remission Predicts a Poor Health-Related Quality of Life in Rheumatoid Arthritis Patients: Results of a Latin American Real World Database
Background/Purpose: Uncontrolled Rheumatoid Arthritis (RA) leads to disability, damage, and poor health-related quality of life (HRQoL). Current treatment recommendations emphasize the importance of achieving remission…Abstract Number: 2019 • 2019 ACR/ARP Annual Meeting
Tenosynovitis at the Metatarsophalangeal Joints, a Novel Feature of RA: Results from an Anatomical and Large Magnetic Resonance Imaging Study of Tendon Sheaths of the Forefoot
Background/Purpose: Recent magnetic resonance imaging (MRI)-studies revealed that tenosynovitis in the hands is associated with rheumatoid arthritis (RA). Although the forefoot is a preferential location…Abstract Number: 481 • 2019 ACR/ARP Annual Meeting
Production of IL17A in Synovial Tissue Correlates with MRI RAMRIS Scores in ACPA Positive Early Rheumatoid Arthritis
Background/Purpose: We previously studied evolution of MRI RAMRIS scores in a group of 28 early rheumatoid (RA) patients treated with first-line infliximab (IFX) versus placebo.…Abstract Number: 2208 • 2019 ACR/ARP Annual Meeting
Mediators of Bone Metabolism (DKK1, OPG, Sclerostin and RANKL) in a Cohort of Patients with Elderly-onset Arthritis
Background/Purpose: Patients with elderly-onset arthritis have greater comorbidity than young patients, with a higher incidence of osteoporosis (OP), probably mediated by increased bone resorption. However,…Abstract Number: 482 • 2019 ACR/ARP Annual Meeting
Antibody Repertoire Sequencing, Antigen Array Analysis, and Cytokine Profiling of Blood from Individuals at High-risk for RA Reveals Candidate Immunoglobulin V Genes, ACPA, and Cytokines That May Promote the Transition to Arthritis
Background/Purpose: The “Targeting Immune Responses for Prevention of RA” (TIP-RA) collaboration studies individuals at high risk for developing rheumatoid arthritis (RA) because of serum anti-citrullinated…Abstract Number: 2269 • 2019 ACR/ARP Annual Meeting
Major Stressors in the Year Prior to Diagnosis Affects RA Characteristics at Presentation and 1 Year
Background/Purpose: Although many RA patients attribute their disease onset to recent life events, results from retrospective studies remain unclear. We compared characteristics of newly diagnosed…Abstract Number: 485 • 2019 ACR/ARP Annual Meeting
Comparison of Clinical Features, Synovial Histology and Immunohistochemistry in Seropositive Arthralgia, Rheumatoid Arthritis, and Osteoarthritis
Background/Purpose: Seropositive arthralgia is defined as joint pain in patients positive for rheumatoid factor (RF) or anti-citrullinated protein antibodies (ACPA). It is a precursor to…Abstract Number: 2324 • 2019 ACR/ARP Annual Meeting
Metabolic Syndrome and Early Arthritis: Frequency, Association with Antibodies Profile and Disease Activity
Background/Purpose: The Metabolic Syndrome (MetS) is an independent factor of cardiovascular morbidity and mortality and most studies show that its prevalence is higher in established…Abstract Number: 486 • 2019 ACR/ARP Annual Meeting
Evolution of Seropositive Arthralgia over Time: Predictors of Evolution to Rheumatoid Arthritis
Background/Purpose: Seropositive arthralgia is defined as joint pain in patients positive for rheumatoid factor (RF) or anti-citrullinated protein antibodies (ACPA). In some individuals it is…Abstract Number: 2361 • 2019 ACR/ARP Annual Meeting
Early Treatment of Rheumatoid Arthritis with Disease-Modifying Anti-Rheumatic Drugs at < 3 versus 3-6 Months from Onset of Symptoms: Results from a Cohort of Hispanics from Puerto Rico
Background/Purpose: There is no doubt that early treatment of rheumatoid arthritis (RA) with disease-modifying anti-rheumatic drugs (DMARDs) is associated with better long-term outcomes. However, the…Abstract Number: 501 • 2019 ACR/ARP Annual Meeting
EULAR Definition of “Arthralgia Suspicious for Progression to Rheumatoid Arthritis” in a Cohort of Patients Included in a Program for Rapid Diagnosis: Role of Ultrasound and Antibodies
Background/Purpose: To evaluate the performance of the EULAR definition of arthralgias suspicious for progression to rheumatoid arthritis (RA) in a group of patients admitted to…Abstract Number: 2369 • 2019 ACR/ARP Annual Meeting
Treatment Patterns with Disease Modifying Anti-rheumatic Drugs in United States Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis
Background/Purpose: Delays in treatment for inflammatory arthritis (IA) are associated with unfavorable outcomes, including impaired quality of life, irreversible joint damage, and disability. Our objective…Abstract Number: 512 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Upadacitinib Monotherapy in MTX-naïve Patients with Early Active RA Receiving Treatment Within 3 Months of Diagnosis: A Post-hoc Analysis of the SELECT-EARLY
Background/Purpose: Early treatment of RA within the therapeutic window (0-3 months from symptom onset), has been associated with improved clinical outcomes and physical function. However,…Abstract Number: 2370 • 2019 ACR/ARP Annual Meeting
Discontinuation of Disease Modifying Drugs in Patients with Incident Rheumatoid Arthritis
Background/Purpose: Treatment of Rheumatoid Arthritis (RA) has undergone a big change in the last two decades in strategies, objectives and therapeutic options, especially with the…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 18
- Next Page »